Design principles for clinical efficacy of cancer nanomedicine: a look into the basics.
Design principles for clinical efficacy of cancer nanomedicine: a look into the basics.
复制标题
DOI:
10.1021/nn4015399
复制
发表时间:
2013-04-23
期刊:
影响因子:
17.1
通讯作者:
Kulkarni, Ashish
中科院分区:
文献类型:
--
作者:
Sengupta, Shiladitya;Kulkarni, Ashish
With the advances in cancer nanomedicine, there is an increasing expectation for clinical translation. However, what are the parameters of a nanomedicine that will define clinical success, which will be measured by increased efficacy and not just ease of delivery or reduction in toxicity? This perspective builds on a fundamental study by Stefanick et al on the significance of the right design principles in the engineering of a nanomedicine, such as peptide-PEG-linker length and ligand density in cellular uptake of liposomal nanoparticles. The perspective addresses additional design parameters that can potentially facilitate clinical translation as well as how emerging insights into tumor biology will inspire the next generation cancer nanomedicines. SUMMARY: As we rapidly race cancer nanomedicines towards the clinics, what are the fundamental design parameters that will influence outcome? What can we learn from antibody-drug conjugates that will facilitate nanomedicines passing the 'efficacy test'? This perspective addresses some of these questions.
登录
查看更多内容
DOI:
10.1038/nrd3958
发表时间:
2013-03
期刊:
Nature reviews. Drug discovery
影响因子:
--
作者:
通讯作者:
--
影响因子:
11.5
作者:
Teicher, Beverly A.;Chari, Ravi V. J.
通讯作者:
Chari, Ravi V. J.
影响因子:
16.1
作者:
Venditto, Vincent J.;Szoka, Francis C., Jr.
通讯作者:
Szoka, Francis C., Jr.
影响因子:
50.3
作者:
Sugahara KN;Teesalu T;Karmali PP;Kotamraju VR;Agemy L;Girard OM;Hanahan D;Mattrey RF;Ruoslahti E
通讯作者:
Ruoslahti E
影响因子:
5.8
作者:
Gref, R;Lück, M;Müller, RH
通讯作者:
Müller, RH